Results 1 to 10 of about 19,691 (120)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021

Neurology and Therapy, 2023
Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary progressive MS ...
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl   +5 more
doaj   +1 more source

Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2

Scientific Reports, 2023
Oligonucleotide mapping via liquid chromatography with UV detection coupled to tandem mass spectrometry (LC-UV-MS/MS) was recently developed to support development of Comirnaty, the world’s first commercial mRNA vaccine which immunizes against the SARS ...
Brian C. Gau, Andrew W. Dawdy, Hanliu Leah Wang, Bradley Bare, Carlos H. Castaneda, Olga V. Friese, Matthew S. Thompson, Thomas F. Lerch, David J. Cirelli, Jason C. Rouse   +9 more
doaj   +1 more source

Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid

Frontiers in Immunology, 2020
The emerging field of biotherapeutics provides successful treatments for various diseases, yet immunogenicity and limited efficacy remain major concerns for many products.
Sharon Yehuda, Vered Padler-Karavani
doaj   +1 more source

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Journal of Translational Medicine, 2021
An amendment to this paper has been published and can be accessed via the original article.
Dobrin D. Draganov, Antonio F. Santidrian, Ivelina Minev, Duong Nguyen, Mehmet Okyay Kilinc, Ivan Petrov, Anna Vyalkova, Elliot Lander, Mark Berman, Boris Minev, Aladar A. Szalay   +10 more
doaj   +1 more source

Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

Frontiers in Immunology, 2014
TweakR is a TNF receptor family member, whose natural ligand is the multifunctional cytokine TWEAK. The growth inhibitory activity observed following TweakR stimulation in certain cancer cell lines and the overexpression of TweakR in many solid tumor ...
James W. Purcell, Han K. Kim, Sonia G. Tanlimco, Minhtam eDoan, Melvin eFox, Peter eLambert, Debra T. Chao, Mien eSho, Keith E. Wilson, Gary C. Starling, Gary C. Starling, Patricia A. Culp   +11 more
doaj   +1 more source

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors

Frontiers in Bioengineering and Biotechnology, 2021
Animal cell-based expression platforms enable the production of complex biomolecules such as recombinant proteins and viral vectors. Although most biotherapeutics are produced in animal cell lines, production in human cell lines is expanding.
Evan Tan, Cara Sze Hui Chin, Zhi Feng Sherman Lim, Say Kong Ng   +3 more
doaj   +1 more source

Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions

Nature Communications, 2021
Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) and GITR ligand (GITRL) regulate immune cell activities, including anti-tumor immune responses.
Feng Wang, Bryant Chau, Sean M. West, Christopher R. Kimberlin, Fei Cao, Flavio Schwarz, Barbara Aguilar, Minhua Han, Winse Morishige, Christine Bee, Gavin Dollinger, Arvind Rajpal, Pavel Strop   +12 more
doaj   +1 more source

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Journal of Translational Medicine, 2019
Background Previous studies have identified IFNγ as an important early barrier to oncolytic viruses including vaccinia. The existing innate and adaptive immune barriers restricting oncolytic virotherapy, however, can be overcome using autologous or ...
Dobrin D. Draganov, Antonio F. Santidrian, Ivelina Minev, Duong Nguyen, Mehmet Okyay Kilinc, Ivan Petrov, Anna Vyalkova, Elliot Lander, Mark Berman, Boris Minev, Aladar A. Szalay   +10 more
doaj   +1 more source

An adapted consensus protein design strategy for identifying globally optimal biotherapeutics

mAbs, 2022
Biotherapeutic optimization, whether to improve general properties or to engineer specific attributes, is a time-consuming process with uncertain outcomes.
Yanyun Liu, Kenny Tsang, Michelle Mays, Gale Hansen, Jeffrey Chiecko, Maureen Crames, Yangjie Wei, Weijie Zhou, Chase Fredrick, James Hu, Dongmei Liu, Douglas Gebhard, Zhong-Fu Huang, Akshita Datar, Anthony Kronkaitis, Kristina Gueneva-Boucheva, Daniel Seeliger, Fei Han, Saurabh Sen, Srinath Kasturirangan, Justin M. Scheer, Andrew E. Nixon, Tadas Panavas, Michael S. Marlow, Sandeep Kumar   +24 more
doaj   +1 more source

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Nature Communications
VISTA, an inhibitory myeloid-T-cell checkpoint, holds promise as a target for cancer immunotherapy. However, its effective targeting has been impeded by issues such as rapid clearance and cytokine release syndrome observed with previous VISTA antibodies.
Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H. Martin, Yoshiko Takeuchi, Kader Thiam, Robert D. Schreiber, Edward H. van der Horst   +17 more
doaj   +1 more source